<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950039</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001265</org_study_id>
    <secondary_id>7-13-CE-17</secondary_id>
    <nct_id>NCT01950039</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Betaine Supplementation</brief_title>
  <official_title>Bedside to Bench and Back: Cardiometabolic Effects of Betaine Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Betaine is important in cellular metabolic pathways. Few epidemiologic studies link betaine&#xD;
      levels to diabetes and cardiovascular disease. Small human studies suggest benefit for&#xD;
      non-alcoholic liver disease. In this study we will determine if administration of betaine&#xD;
      improves metabolic measures, liver fat and/or endothelial function in humans with glucose&#xD;
      intolerance who are overweight.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single site, prospective, randomized (1:1), double masked, placebo controlled&#xD;
      trial to assess metabolic effects of betaine compared to placebo on glycemia and insulin&#xD;
      sensitivity, liver fat and endothelial function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting and 2 Hour Glucose Levels, Comparing Baseline and 12 Weeks.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Glucose levels were analyzed in the fasting state and two hours after glucose load, comparing baseline to 12 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Glucose AUC at 12 Weeks From Baseline (Glucose Tolerance)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Glucose tolerance was assessed by oral glucose tolerance, assessed using the change from baseline for fasting and 2 hour glucose, and change in Glucose AUC at 12 weeks from baseline was measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Fat, Change From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Intrahepatic triglyceride levels were assessed by magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (Siemens 3T TIM Skyra, software version VD13; Siemens, Erlangen, Germany).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Brachial artery reactivity to flow and nitroglycerin stimuli, assessed as percent change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Euglycemic hyperinsulinemic clamp at baseline and at end of study (12 weeks) for assessment of:&#xD;
glucose disposal (M) at low (25 mU/m2/min) and high (180 mU/m2/min) insulin infusion rates, reported as raw data&#xD;
measurement of endogenous glucose production at basal and low insulin infusion (25 mU/m2/min), reported as change from measures at baseline of individual study days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Obesity</condition>
  <condition>Dysglycemia</condition>
  <arm_group>
    <arm_group_label>Betaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betaine</intervention_name>
    <description>Betaine or placebo administered orally in divided doses over 12 weeks</description>
    <arm_group_label>Betaine</arm_group_label>
    <other_name>trimethyl glycine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally in divided doses over 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Men and women aged 21-65 years old;&#xD;
&#xD;
          -  2) Dysglycemia/prediabetes is defined as impaired fasting glucose (≥100 mg/dl),&#xD;
             impaired glucose tolerance (2 hour post 75 g oral glucose load 140-200 mg/dl) or HbA1c&#xD;
             5.7-6.5%);&#xD;
&#xD;
          -  3) overweight to grade 3 obesity (BMI 25 to 45 kg/m2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) cystathionine beta-synthase (CBS deficiency);&#xD;
&#xD;
          -  2) Presence of liver disease other than NAFLD;&#xD;
&#xD;
          -  3) Use of medications causing steatosis;&#xD;
&#xD;
          -  4) Known alcohol consumption ≥ 2 drink per day;&#xD;
&#xD;
          -  5) Use of medications known to cause insulin resistance;&#xD;
&#xD;
          -  6) Use of weight loss drugs (or program) within 3 months of screening;&#xD;
&#xD;
          -  7) Treatment with any experimental drug within the past 6 months;&#xD;
&#xD;
          -  8) Subjects must be willing to abstain from use of phosphodiesterase type 5 (PDE-5)&#xD;
             inhibitors;&#xD;
&#xD;
          -  9) Pregnancy or lactation, and women of child bearing potential must use adequate&#xD;
             contraception;&#xD;
&#xD;
          -  10) Surgery within 30 days of screening;&#xD;
&#xD;
          -  11) Heart disease defined as New York Heart Association Class III or IV cardiac status&#xD;
             or hospitalization for congestive heart failure, unstable angina, myocardial&#xD;
             infarction, cerebrovascular accident, transient ischemic attack or any&#xD;
             revascularization within 6 months;&#xD;
&#xD;
          -  12) Uncontrolled hypertension;&#xD;
&#xD;
          -  13) eGFR &lt;60; 14) History of acquired immune deficiency syndrome;&#xD;
&#xD;
          -  15) History of malignancy within 5 years;&#xD;
&#xD;
          -  16) Hemoglobin &lt;12 g/dL (males), &lt;10 g/dL (females);&#xD;
&#xD;
          -  17) Triglycerides (TG) &gt;500 mg/dL;&#xD;
&#xD;
          -  18) Poor mental function or any other reason to expect patient difficulty in complying&#xD;
             with study requirements;&#xD;
&#xD;
          -  19) Metal clips or implants that preclude magnetic resonance imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Joslin Diabetes Center and Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Grizales AM, Patti ME, Lin AP, Beckman JA, Sahni VA, Cloutier E, Fowler KM, Dreyfuss JM, Pan H, Kozuka C, Lee A, Basu R, Pober DM, Gerszten RE, Goldfine AB. Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes. J Clin Endocrinol Metab. 2018 Aug 1;103(8):3038-3049. doi: 10.1210/jc.2018-00507.</citation>
    <PMID>29860335</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <results_first_submitted>August 16, 2018</results_first_submitted>
  <results_first_submitted_qc>March 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2021</results_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Glucose Intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betaine</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT01950039/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 9, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT01950039/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study subjects with overweight and T2D risk factors were screened for dysglycemia and enrolled at 1 site in the US.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Betaine</title>
          <description>Betaine:&#xD;
Participants were instructed to take betaine 3300 mg (10 ml) orally twice daily for 10 days, then 4950 mg (15 ml) orally twice daily through 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Participants were instructed to take identical amounts and appearance of placebo through 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Study Drug Initiated</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Clamp</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed MRI</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Endothelial Evaluation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline clinical characteristics were similar between groups.</population>
      <group_list>
        <group group_id="B1">
          <title>Betaine</title>
          <description>Betaine:&#xD;
Participants were instructed to take betaine 3300 mg (10 ml) orally twice daily for 10 days, then 4950 mg (15 ml) orally twice daily through 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Participants were instructed to take identical amounts and appearance of placebo through 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="7"/>
                    <measurement group_id="B2" value="57" spread="8"/>
                    <measurement group_id="B3" value="59" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race and Ethnicity</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Participants were recruited from the New England region.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fasting and 2 Hour Glucose Levels, Comparing Baseline and 12 Weeks.</title>
        <description>Glucose levels were analyzed in the fasting state and two hours after glucose load, comparing baseline to 12 weeks.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betaine</title>
            <description>Betaine:&#xD;
Participants were instructed to take betaine 3300 mg (10 ml) orally twice daily for 10 days, then 4950 mg (15 ml) orally twice daily through 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Participants were instructed to take identical amounts and appearance of placebo through 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting and 2 Hour Glucose Levels, Comparing Baseline and 12 Weeks.</title>
          <description>Glucose levels were analyzed in the fasting state and two hours after glucose load, comparing baseline to 12 weeks.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fasting glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" lower_limit="-12" upper_limit="1"/>
                    <measurement group_id="O2" value="3" lower_limit="-4" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-hour glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="-10" upper_limit="25"/>
                    <measurement group_id="O2" value="-4" lower_limit="-22" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Glucose AUC at 12 Weeks From Baseline (Glucose Tolerance)</title>
        <description>Glucose tolerance was assessed by oral glucose tolerance, assessed using the change from baseline for fasting and 2 hour glucose, and change in Glucose AUC at 12 weeks from baseline was measured.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betaine</title>
            <description>Betaine:&#xD;
Participants were instructed to take betaine 3300 mg (10 ml) orally twice daily for 10 days, then 4950 mg (15 ml) orally twice daily through 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Participants were instructed to take identical amounts and appearance of placebo through 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose AUC at 12 Weeks From Baseline (Glucose Tolerance)</title>
          <description>Glucose tolerance was assessed by oral glucose tolerance, assessed using the change from baseline for fasting and 2 hour glucose, and change in Glucose AUC at 12 weeks from baseline was measured.</description>
          <units>mg*min/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340" lower_limit="-993" upper_limit="1672"/>
                    <measurement group_id="O2" value="-413" lower_limit="-1749" upper_limit="923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Fat, Change From Baseline</title>
        <description>Intrahepatic triglyceride levels were assessed by magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (Siemens 3T TIM Skyra, software version VD13; Siemens, Erlangen, Germany).</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betaine</title>
            <description>Betaine:&#xD;
Participants were instructed to take betaine 3300 mg (10 ml) orally twice daily for 10 days, then 4950 mg (15 ml) orally twice daily through 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Participants were instructed to take identical amounts and appearance of placebo through 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Fat, Change From Baseline</title>
          <description>Intrahepatic triglyceride levels were assessed by magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (Siemens 3T TIM Skyra, software version VD13; Siemens, Erlangen, Germany).</description>
          <units>percent change in hepatic triglyceride</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.02"/>
                    <measurement group_id="O2" value="-0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Function</title>
        <description>Brachial artery reactivity to flow and nitroglycerin stimuli, assessed as percent change from baseline</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>One participant in the placebo group was not able to complete nitroglycerine-mediated dilation assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Betaine</title>
            <description>Betaine:&#xD;
Participants were instructed to take betaine 3300 mg (10 ml) orally twice daily for 10 days, then 4950 mg (15 ml) orally twice daily through 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Participants were instructed to take identical amounts and appearance of placebo through 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Function</title>
          <description>Brachial artery reactivity to flow and nitroglycerin stimuli, assessed as percent change from baseline</description>
          <population>One participant in the placebo group was not able to complete nitroglycerine-mediated dilation assessment.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change in flow-mediated dilation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-3.3" upper_limit="2.3"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-4.7" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change in nitroglycerine-mediated dilation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-4.0" upper_limit="2.1"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-4.1" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity</title>
        <description>Euglycemic hyperinsulinemic clamp at baseline and at end of study (12 weeks) for assessment of:&#xD;
glucose disposal (M) at low (25 mU/m2/min) and high (180 mU/m2/min) insulin infusion rates, reported as raw data&#xD;
measurement of endogenous glucose production at basal and low insulin infusion (25 mU/m2/min), reported as change from measures at baseline of individual study days</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Betaine</title>
            <description>Betaine:&#xD;
Participants were instructed to take betaine 3300 mg (10 ml) orally twice daily for 10 days, then 4950 mg (15 ml) orally twice daily through 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Participants were instructed to take identical amounts and appearance of placebo through 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Euglycemic hyperinsulinemic clamp at baseline and at end of study (12 weeks) for assessment of:&#xD;
glucose disposal (M) at low (25 mU/m2/min) and high (180 mU/m2/min) insulin infusion rates, reported as raw data&#xD;
measurement of endogenous glucose production at basal and low insulin infusion (25 mU/m2/min), reported as change from measures at baseline of individual study days</description>
          <units>umol/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose Utilization (M), 25 mU/m2/min, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4" spread="16.5"/>
                    <measurement group_id="O2" value="62.8" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Utilization (M), 25 mU/m2/min, 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.9" spread="16.9"/>
                    <measurement group_id="O2" value="73.5" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Utilization (M), 180 mU/m2/min, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406.8" spread="30.4"/>
                    <measurement group_id="O2" value="332.6" spread="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Utilization (M), 180 mU/m2/min, 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458.1" spread="38.7"/>
                    <measurement group_id="O2" value="393.7" spread="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous Glucose Production, basal insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03" spread=".09"/>
                    <measurement group_id="O2" value="-0.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endogenous Glucose Production, 25 mU/m2/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.12"/>
                    <measurement group_id="O2" value="-0.12" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for 14 weeks (during study drug administration and for 2 weeks after last study drug).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Betaine</title>
          <description>Betaine:&#xD;
Participants were instructed to take betaine 3300 mg (10 ml) orally twice daily for 10 days, then 4950 mg (15 ml) orally twice daily through 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Participants were instructed to take identical amounts and appearance of placebo through 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GI motility and defecation conditions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic and hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract signs and symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorders NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Respiratory tract infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Elizabeth Patti MD</name_or_title>
      <organization>Joslin Diabetes Center</organization>
      <phone>617 309 2635</phone>
      <email>mary.elizabeth.patti@joslin.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

